Latest Breaking News On - Presented today - Page 4 : comparemela.com

(0) Data to be Presented Today at the ASGCT 24th Annual Meeting Demonstrated No Dose-Limiting Toxicity with Encouraging Clinical Activity in First 5 Patients Treated; Final Data Readout Expected by End of 2021 BEDMINSTER, N.J. and SINGAPORE, May 14, 2021) testing TT11X in patients with CD30+ lymphomas. The results will be presented today at the 24 th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT 2021). The presentation at ASGCT 2021 will highlight data from six patients treated with the therapy. The results demonstrated a favorable safety profile with encouraging clinical activity even at lower dose levels in heavily pre-treated relapsed / refractory (R/R) CD30+ lymphoma patients. The dataset includes three patients dosed at the lowest dosing level (4 × 10

United statesMalcolm brennerIngrid mezoJohanna bennettCarlos ramosDave schemeliaAllogeneic vstsKostenloser wertpapierhandelJeffreyh buchalterTiberend strategic advisors incTessa scientific coMeeting of american society geneUs food drug administrationBaylor college of medicinePresented todayEncouraging clinical activity